Teosyal Redensity 2 PureSense 2 x 1 ml
Teosyal Redensity 2 PureSense is recommended for injection into the periorbital area or tear ducts. The injection technique generally involves microinjections into the skin. The effect of the dermal filler is visible shortly after the first session without the need for touch-ups. In most cases, the effect lasts up to 12 months, but this is highly individual and depends on factors such as age, skin type, lifestyle, etc.
Benefits:
- Dark circles around the eyes
- Tear troughs
- Palleboplasty
- Minimal under-eye bags
Composition:
- Crosslinked Hyaluronic Acid (15 mg/ml)
- Lidocaine (0.3%)
- Crosslinking Degree (1/6)
This uniquely formulated gel contains crosslinked and unmodified hyaluronic acid, as well as:
- 8 amino acids (glycine, lysine, threonine, proline, isoleucine, leucine, valine, and arginine)
- 3 antioxidants (glutathione, N-acetyl-L-cysteine, and alpha-lipoic acid)
- 2 minerals (zinc and copper)
- Vitamin B6 and the local anesthetic lidocaine.
The sterile gel has a completely transparent and slightly hygroscopic texture, preventing swelling after injection. Its viscoelastic properties ensure easy and uniform diffusion and controlled gel placement.
Areas:
- periorbital area
- tear ducts
- eye circles
Format:
2 syringes of 1 ml
Manufacturer:
Teoxane
Dermo-Restructuring Complex
The Dermo-Restructuring Complex is highly compatible with hyaluronic acid and prevents hypersensitivity reactions. Amino acids stimulate collagen production and participate in the healing and tissue remodeling process. Antioxidants, in turn, prevent damage to cellular structure caused by free radicals, stress, pollution, poor diet, etc. Added minerals zinc and copper actively participate in the synthesis of new cells. Vitamin B6 is essential for energy production for cellular metabolism in the dermis. Lidocaine within the composition ensures maximum patient comfort during treatment of the sensitive eye area. The exceptional purity of the gel prevents the formation of free radicals under the skin.
